Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P05455
UPID:
LA_HUMAN
Alternative names:
La autoantigen; La ribonucleoprotein; Sjoegren syndrome type B antigen
Alternative UPACC:
P05455; Q15367; Q53XJ4
Background:
The Lupus La protein, also known as La autoantigen, La ribonucleoprotein, and Sjoegren syndrome type B antigen, plays a crucial role in RNA biology. It binds to the 3' poly(U) terminus of nascent RNA polymerase III transcripts, safeguarding them from exonuclease digestion and aiding in their folding and maturation. Additionally, during Coxsackievirus B3 infection, it interacts with the viral internal ribosome entry site (IRES) to enhance IRES-mediated translation.
Therapeutic significance:
Understanding the role of Lupus La protein could open doors to potential therapeutic strategies.